z-logo
Premium
NR5A2 discovering compounds that block tumor growth in PDAC
Author(s) -
Fletterick Robert
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24639
Subject(s) - transcription factor , liver receptor homolog 1 , cancer research , enhancer , reprogramming , nuclear receptor , medicine , small heterodimer partner , oncogene , farnesoid x receptor , microbiology and biotechnology , cancer , biology , cell , cell cycle , gene , genetics
Pancreatic cancers depend on driver molecules, oncogene proteins such as RAS. NR5A2 protein is a transcription factor and either activates or inhibits transcription through actions at hundreds of enhancers. It has unusual properties with effects appearing in multiple signaling networks. NR5A2 is a pluripotency reprogramming factor in the class nuclear receptor. Its controlling hormone is PIP3. Experiments suggest NR5A2 activation drives PDAC and inhibitors blunt cancer cell proliferation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here